Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients

BMC Genomics

Table 2 Association of miRNA expression with the clinic-pathological features of PCa patients

Clinical features	Case no.	miR-19a		miR-374b
Clinical features	Case no.		P		P
Age (years)
<60	67	4.87 ± 0.62	0.43	3.81 ± 1.19	0.23
≥60	37	4.75 ± 0.97	0.43	4.08 ± 1.05	0.23
Serum PSA levels (ng/ml) ^#
<10	21	4.80 ± 0.66	0.020^*	4.00 ± 0.81	0.98
≥10	82	5.16 ± 0.44	0.020^*	4.00 ± 1.17	0.98
Gleason score ^#
<8	81	4.91 ± 0.44	0.16	3.01 ± 1.571	0.003^**
≥8	18	4.68 ± 1.11	0.16	4.28 ± 0.692	0.003^**
Clinical stage ^#
<T2A	59	4.76 ± 0.65	0.11	3.94 ± 0.146	0.21
≥T2A	41	4.96 ± 0.55	0.11	4.21 ± 0.856	0.21
Pathological stage ^#
T2A-T2C	65	4.82 ± 0.52	0.46	3.64 ± 1.480	0.039^*
T3A-T4	35	4.91 ± 0.80	0.46	4.21 ± 0.775	0.039^*
Metastasis ^#
No	86	4.89 ± 0.49	0.11	4.25 ± 0.076	0.001^**
Yes	18	4.57 ± 1.50	0.11	2.70 ± 1.661	0.001^**
Overall survival
Alived	94	4.91 ± 0.55	0.13	4.13 ± 0.096	0.020^*
Dead	10	4.04 ± 1.66	0.13	2.65 ± 1.655	0.020^*
PSA failure ^#
Negative	72	4.88 ± 0.45	0.90	4.31 ± 0.081	0.002^**
Positive	27	4.86 ± 0.90	0.90	3.36 ± 1.419	0.002^**

ISSN: 1471-2164